Chiusura precedente | 2,3700 |
Aperto | 2,4300 |
Denaro | 2,4000 x 100 |
Lettera | 2,5300 x 100 |
Min-Max giorno | 2,3900 - 2,4900 |
Intervallo di 52 settimane | 2,1500 - 4,8000 |
Volume | |
Media Volume | 34.636 |
Capitalizzazione | 173,48M |
Beta (5 anni mensile) | 0,71 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -0,4200 |
Prossima data utili | N/D |
Rendimento e dividendo (futuro) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | 9,25 |
MIAMI, Oct. 03, 2023 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 63rd Emerging Growth Conference on October 4th and 5th, 2023. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the conference here. Submit Questions for any of the presenting
JERUSALEM, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that a patient with advanced inoperable pancreatic cancer has been treated in a clinical trial at Hadassah Medical Center in Jerusalem, Israel. The trial is designed for a broad range of solid tumor patients who do not qualify for participation in other existing trials or who do not
– Treated the first patient with advanced inoperable pancreatic cancer in a safety and feasibility trial in Canada in April – – 89% CR, two-year local recurrence-free survival of 77%, and no treatment-related grade 2 or higher late-onset toxicity reported from an analysis of four feasibility trials in 71 patients with unresectable skin and head and neck cancers – – Valuable land grant received in Jerusalem to enable a standalone company headquarters and future increased manufacturing capacity –